# with extensive-stage small cell lung cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer

> No upcoming FDA catalysts in with extensive-stage small cell lung cancer; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for with extensive-stage small cell lung cancer?

No upcoming FDA catalysts in with extensive-stage small cell lung cancer; 2 past events are recorded. Press release filed with the SEC (EX-99): "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) initiation of enrollment in ALISCA®-Lung2, a Phase I/II trial of alisertib in combination with paclitaxel for the treatment of patients with extensive stage small cell lung cancer (Q3 2026)" [Calendar and source filings](https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-026282, https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm (retrieved 2026-11-12). Last confirmed 2026-08-06. Cite: https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [Alisertib trial start](https://sec-api.dev/pdufa/alisertib) | PBYI | with extensive-stage small cell lung cancer | completed | "In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm)) |
| Q3 2026 | [Alisertib trial start](https://sec-api.dev/pdufa/alisertib) | PBYI | with extensive stage small cell lung cancer | scheduled | "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) initiation of enrollment in ALISCA®-Lung2, a Phase I/II trial of alisertib in combination with paclitaxel for the treatment of patients with extensive stage small cell lung cancer (Q3 2026)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm)) |

## Drugs

- [Alisertib](https://sec-api.dev/pdufa/alisertib) (PBYI)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "with extensive-stage small cell lung cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer

```bibtex
@misc{secapidev_indications_with_extensive_stage_small_cell_lung_cancer_20261116,
  title        = {with extensive-stage small cell lung cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_with_extensive_stage_small_cell_lung_cancer_20261116","title":"with extensive-stage small cell lung cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
